Population-based secular trends in lower-extremity amputation for diabetes and peripheral artery disease
- PMID: 31481423
- PMCID: PMC6721859
- DOI: 10.1503/cmaj.190134
Population-based secular trends in lower-extremity amputation for diabetes and peripheral artery disease
Abstract
Background: The evolving clinical burden of limb loss secondary to diabetes and peripheral artery disease remains poorly characterized. We sought to examine secular trends in the rate of lower-extremity amputations related to diabetes, peripheral artery disease or both.
Methods: We included all individuals aged 40 years and older who underwent lower-extremity amputations related to diabetes or peripheral artery disease in Ontario, Canada (2005-2016). We identified patients and amputations through deterministic linkage of administrative health databases. Quarterly rates (per 100 000 individuals aged ≥ 40 yr) of any (major or minor) amputation and of major amputations alone were calculated. We used time-series analyses with exponential smoothing models to characterize secular trends and forecast 2 years forward in time.
Results: A total of 20 062 patients underwent any lower-extremity amputation, of which 12 786 (63.7%) underwent a major (above ankle) amputation. Diabetes was present in 81.8%, peripheral artery disease in 93.8%, and both diabetes and peripheral artery disease in 75.6%. The rate of any amputation initially declined from 9.88 to 8.62 per 100 000 between Q2 of 2005 and Q4 of 2010, but increased again by Q1 of 2016 to 10.0 per 100 000 (p = 0.003). We observed a significant increase in the rate of any amputation among patients with diabetes, peripheral artery disease, and both diabetes and peripheral artery disease. Major amputations did not significantly change among patients with diabetes, peripheral artery disease or both.
Interpretation: Lower-extremity amputations related to diabetes, peripheral artery disease or both have increased over the last decade. These data support renewed efforts to prevent and decrease the burden of limb loss.
© 2019 Joule Inc. or its licensors.
Conflict of interest statement
Competing interests: Naveed Sattar reports personal fees from Amgen, AstraZeneca, Eli Lilly, Janssen, Napp Pharmaceuticals, Novo Nordisk and Sanofi, and grants and personal fees from Boehringer Ingelheim outside the submitted work. No other competing interests were declared.
Figures
Comment in
-
Sounding the alarm on rising diabetes-related amputations.CMAJ. 2019 Sep 3;191(35):E953-E954. doi: 10.1503/cmaj.191064. CMAJ. 2019. PMID: 32392480 Free PMC article. No abstract available.
References
-
- Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med 2017;376:2367–75. - PubMed
-
- Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA 2005;293:217–28. - PubMed
-
- Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, et al. The global burden of diabetic foot disease. Lancet 2005;366:1719–24. - PubMed
-
- Jeffcoate WJ, Chipchase SY, Ince P, et al. Assessing the outcome of the management of diabetic foot ulcers using ulcer-related and person-related measures. Diabetes Care 2006;29:1784–7. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical